2. Academic Validation
  3. Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model

Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model

  • Cancer Discov. 2025 Jan 13;15(1):162-178. doi: 10.1158/2159-8290.CD-24-0489.
Yonghong Liu 1,  Jincheng Han 1,  Wen-Hao Hsu 1,  Kyle A LaBella 1,  Pingna Deng 1,  Xiaoying Shang 1,  Paulino Tallón de Lara 1,  Li Cai 1,  Shan Jiang 1,  Ronald A DePinho 1
Affiliations

Affiliation

  • 1 Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
PMID: 39348506 DOI: 10.1158/2159-8290.CD-24-0489
Abstract

Clinically available KRAS* inhibitors and IO agents alleviated the immunosuppressive tumor microenvironment in PDAC. Profound tumor regression and prolonged survival in an autochthonous PDAC model provide a compelling rationale for combining KRAS* inhibition with IO agents targeting multiple arms of the immunity cycle to combat PDAC.

Figures
Products